Studies on the Coumarin Anticoagulant Drugs : A Comparison of the Pharmacodynamics of Dicumarol and Warfarin in Man

Summary

The pharmacodynamic and prothrombinopénie effects of the coumarin anticoagulant drugs warfarin and dicumarol were compared in man by means of specific chemical assays for the drugs and the Quick prothrombin time for the response. The absorption of warfarin was rapid and complete, and the prothrombinopénie response was similar after administration by any route. Absorption of dicumarol as a solution or powder was rapid while as whole tablets it was often slow. Dicumarol in solution taken orally produced higher maximum concentrations of drug in plasma, more rapid absorption rates, less unchanged drug in stool and an earlier and greater prothrombin complex response than the tablets. Only a slight effect was produced by varying the formulation of warfarin. In all subjects 15 to 30% of the oral dose of dicumarol was recovered as unchanged drug in the stool. Unchanged warfarin was not recovered from the stool in any experiment.

The apparent volume of distribution (Vd) for warfarin and high doses of dicumarol was about 12.5% of body weight, approximately the size of the albumin space. The long half-time of disappearance (t½) of both drugs, their prolonged duration of action, small volume of distribution, and lack of excretion of unchanged drug in the urine are probably related to their high degree of binding to plasma proteins. The t½ and Vd for warfarin are independent of dose size; the unusual dependency of these parameters on dose size with dicumarol suggests tissue uptake, perhaps by the reticuloendothelial system.

A good correlation was found between the t½ of warfarin and dicumarol and the magnitude and duration of response. Up to a certain point increasing the dose of these drugs hastened the occurrence of hypoprothrombinemia ; beyond a dose size characteristic for each individual no further hastening could be obtained.

A substance extracted from the stool of subjects receiving dicumarol intravenously and orally is probably a metabolite of the drug.

• References

• 1 Owren P. A. Indications for anticoagulant therapy. New Engl. J. Med. 268: 1173 1228 1963;
• 2 Butt H. R, Allen E. V, Bollman J. L. Apreparation from spoiled sweet clover (3,3’-methylene-bis-(4-hydroxycoumarin)) which prolongs coagulation and prothrombin time of the blood: preliminary report of experimental and clinical studies. Proc. Mayo Clin. 16: 388 1941;
• 3 Wright I. S, Marple C. D, Beck D. F. Report of the committee for the evaluation of anticoagulants in the treatment of coronary thrombosis with myocardial infarction. Amer. Heart J. 36: 801 1948;
• 4 Bjerkelund C. J. The effect of long term treatment with dicumarol in myocardial infarction. Acta med. scand. 158 Suppl. 330 1957;
• 5 Working Party of the Medical Research Council on Anticoagulant Therapy in Coronary Thrombosis. Long-term anticoagulant therapy. Brit. med. J. II: 239 1959;
• 6 Borchgrevink C. F. Long-term anticoagulant therapy in angina pectoris and myocardial infarction: a clinical trial of intensive versus moderate treatment. Acta med. scand. 168 Suppl. 359 1960;
• 7 Alexander B, Wessler S. A guide to anticoagulant therapy. Circulation 24: 123 1961;
• 8 Douglas A. S. Anticoagulant Therapy. F. A. Davis; Philadelphia: 1962: 192.
• 9 Nicholson J. H. Clinical experiences with anticoagulants: a comparison of Coumadin (warfarin) sodium and Dicumarol (bishydroxycoumarin). Angiology 08: 456 1957;
• 10 Shapiro S. The administration of hypoprothrombinemia-inducing drugs. Angiology 06: 500 1955;
• 11 O’Reilly R. A, Aggeler P. M, Hoag M. S, Leong L. Studies on the coumarin anticoagulant drugs : the assay of warfarin and its biologic application. Thrombos. Diathes. haemorrh. (Stuttg) 08: 82 1962;
• 12 Axelrod J, Cooper J. R, Brodie B. B. Estimation of dicumarol, 3, 3¹-methylenebis (4-hydroxycoumarin) in biological fluids. Proc. Soc. exp. Biol. 70: 693 1949;
• 13 Quick A. J. The Physiology and Pathology of Hemostasis. Lea and Febeger; Philadelphia: 1951
• 14 O’Reilly R. A, Aggeler P. M, Hoag M. S, Leong L. Studies on warfarin and dicumarol. Clin. Res. 10: 108 1962; (abstract).
• 15 O’Reilly R. A, Aggeler P. M, Leong L. S. The distribution and elimination of warfarin and dicumarol. Clin. Res. 11: 93 1963; (abstract).
• 16 Craig L. C. Identification of small amounts of organic compounds by distribution studies. II. Separation by counter-current distribution. J. biol. Chem. 155: 519 1944;
• 17 Dominguez R, Pomerene E. Calculation of the rate of absorption of exogenous creatinine. Proc. Soc. exp. Biol. 60: 173 1945;
• 18 O’Reilly R. A, Aggeler P. M, Leong L. S. Studies on the coumarin anticoagulant drugs: the pharmacodynamics of warfarin in man. J. clin. Invest. 42: 1542 1963;
• 19 Link K. P. The discovery of dicumarol and its sequels. Circulation 19: 97 1959;
• 20 Weiner M, Shapiro S, Axelrod J, Cooper J. R, Brodie B. B. The physiological disposition of dicumarol in man. J. Pharmacol, exp. Ther. 99: 409 1950;
• 21 Weiner M, Brodie B. B, Burns J. J. A comparative study of hypoprothrombinemic agents : the physiologic disposition and chemical pharmacology of coumarin and indanedione compounds in thrombosis and embolism. Proceedings of the I. International Conference. Koller T. h, Merz W. R. Eds. Schwabe, Basel: 1955: 181.
• 22 Weiner M. Pharmacological considerations of antithrombotic therapy. Advanc. pharmacol. 01: 277 1962;
• 23 Weiner M. Personal communication. 1963
• 24 Levy G. Availability of spironolactone given by mouth. Lancet II: 723 1962;
• 25 Eble J. N. Studies on warfarin and warfarin sodium. Thesis Ph. D. University of Wisconsin; 1954
• 26 Brodie B. B, Hogben C. A. Some physico-chemical factors in drug action. J. Pharm. Pharmacol. 09: 345 1957;
• 27 Schanker L. S. On the mechanism of absorption of drugs from the gastrointestinal tract. J. med. pharm. Chem. 02: 343 1960;
• 28 Nelson E. Kinetics of drug absorption, distribution, metabolism, and excretion. J. pharm. Sci. 50: 181 1961;
• 29 Berson S. A, Yalow R. S, Schreiber S. S, Post J. Tracer experiments with I¹³¹ labeled human serum albumin: distribution and degradation studies. J. clin. Invest. 32: 746 1953;
• 30 Spitzy K. H, Hitzenberger G. The distribution volume of some antibiotics. Antibiot. Ann. 996 (1957-58).
• 31 Abraham E. P, Newton GGF. Chemistry and classification of antibiotics. Brit. med. Bull. 16: 3 1960;
• 32 Schächter D, Freinkel N, Schwartz I. L. Movement of inulin between plasma and interstitial fluid. Amer. J. Physiol. 160: 532 1950;
• 33 Spratt J. L, Okita G. T. Protein binding of radioactive digitoxin. J. Pharmacol, exp. Ther. 124: 109 1958;
• 34 Bedford G, Busfield D, Child K. J, MacGregor I, Sutherland P, Tomich E. G. Studies on the biological disposition of griseofulvin, an oral antifungal agent. A. M. A. Arch. Derm. 81: 735 1960;
• 35 Merck Index of Chemicals and Drugs. 7th. Ed. Merck & Co., Inc; Rahway, New Jersey: 1960: 424.
• 36 McNall E. G. Metabolic studies on griseofulvin and its mechanism of action. Antibiot. Ann. 674 (1959-60).
• 37 Benacerraf B. Quantitative aspects of phagocytosis in Liver Function: A Symposium on Approaches to the Quantitative Description of Liver Function. Brauer R. W. Ed. American Institute of Biological Sciences; Washington, D. C: 1958: 205.
• 38 Link K. P. Personal communication. 1962
• 39 Hausner E. P, Shafer C. L, Corson M, Johnson O, Trujillo T, Langham W. Clinical evalution of dicumarinyl derivatives with a metabolic study of the radioactively labeled anticoagulants in animals. Circulation 03: 171 1951;
• 40 Lee C. C, Trevoy L. W, Spinks JWT, Jaques L. B. Dicumarol labelled with C¹⁴ . Proc. Soc. exp. Biol. 74: 151 1950;
• 41 de Takats G. Heparin tolerance: a test of the clotting mechanism. Surg. Gynec. Obstet. 77: 31 1943;